The objective of the present study was to evaluate the safety and therapeutic potential of intravitreal use of a bone marrow mononuclear fraction containing CD34+ (BMMF) in ten patients with Stargardt macular dystrophy. The gene discussed is CD34; the disease is Stargardt disease.